ROBOSENSE
4.8.2020 20:02:06 CEST | Business Wire | Press release
RoboSense http://www.robosense.ai/ , the leading provider of smart LiDAR sensor, today launched an 80 laser-beam 3D sensing LiDAR ready for customer delivery with early-bird price of $12,800 (limited offer till 31st August, 2020), and standard price of $15,800. The timing of announcing this favorable package also marks the company's 6-year anniversary. The performance of the RS-Ruby Lite is close to that of the 128 laser-beam LiDAR RS-Ruby, with a vertical angular resolution of 0.1 degrees and 160m@10% ranging ability (with the longest detection range of 230 meters), making it suitable to address medium-and-high-speed autonomous driving applications with a price much more affordable to accelerate the commercialization of smart and safe transportation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200804005578/en/
Inheriting The Superb Performance Of The 128 Laser-Beam LiDAR RS-Ruby
The RS-Ruby Lite has inherited the superb performance from the 128 laser beams LiDAR RS-Ruby, whereas, it collects reduced amounts of but essential data of the environment and has lower requirements on the bandwidth(to 75%), perfectly fulfills environment sensing requirements of self-driving passenger cars, driverless mining cars, driverless trucks, vehicle-to-infrastructure, etc.
- 0.1° Vertical Angular Resolution
To date, 0.1° vertical angular resolution is the highest standard among all mechanical LiDARs available on the global market. The 80 laser-beam LiDAR RS-Ruby Lite also boasts an ultra-high angular resolution of 0.1° with 40 laser beams scanning the front area of the car.
- 160m Measurement Range @10% Reflectivity
The RS-Ruby Lite can detect objects even in 230 meters away.
- Reflection Intensity Reaches A Perfect Balance Of Consistency And Distinction
Inheriting from the RS-Ruby's advanced hardware and signal processing technology, the reflection intensity of RS-Ruby Lite reaches a perfect balance between consistency and distinction, further facilitating accurate road sign extraction and localization.
- Anti-Interference Capability Under Multi-LiDAR Jamming & Various Ambient Lights
With special laser encryption technology to filter interference signals, the RS-Ruby Lite addresses interference under multi-LiDAR jamming & various ambient lights.
Availability And Pricing
Thanks to the proven technology platform of the 128 laser-beams LiDAR RS-Ruby and the modular design, the mass-production-ready RS-Ruby Lite is able to benefit from much lower material and process costs. The sensor has undergone a large number of verification and reliability tests and is proved with outstanding stability and reliability. The product is also backed with sufficient production capacity.
High resolution and performance LiDAR sensor with affordable price is the key to move medium-and-high-speed autonomous driving projects from R&D towards commercial viability. The RS-Ruby Lite is the most competitive and cost-effective high laser-beam LiDAR, making it ideal for medium-and-high-speed autonomous driving applications.
The RS-Ruby Lite is available for sale and ready for delivery. For orders please visit www.robosense.ai/buy or contact a RoboSense account manager.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to possess outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability more superior to humans.
Attracted an all-star team from leading corporations and institutions around the world, there are 500+ employees in 6 global locations-Shenzhen, Beijing, Shanghai, Suzhou, Stuttgart, and Silicon Valley to support RoboSense's fast-growing in innovation and development. Until 2019, RoboSense owns more than 500 patents globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005578/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom